Maddyness: An interview with our CEO Sam Windsor

Ignota Labs In-Licenses First Proprietary Asset: Pioneering PDE9A Inhibitor Set to Transform Multi-Action Therapeutics

PharmaPhorum: Why drugs fail

AI for Pharma Growth: Rescuing failed drug projects

Ignota Labs accepted for the 2024 cohort of TechBio Boost

Improved Detection of Drug-Induced Liver Injury

Ignota Labs winners at Royal Society of Chemistry’s Emerging Technologies Competition 2024

Ignota Labs named Milner Therapeutics Institute affiliated company